AUS
NZ
UK
CA
USA
IND
Enlitic, Inc. (ASX:ENL), a US-based AI medical imaging software firm listed on the Australian Securities Exchange, has issued its Notice of Extraordinary General Meeting set for 29 July 2026. The meeting seeks shareholder approval for a series of capital restructuring initiatives announced on 3 July 2026, including a conditional placement aiming to raise approximately A$15 million, a security purchase plan targeting up to A$1 million, conversion of A$10 million in convertible notes into CDIs, and a 10-for-1 share consolidation. Upon obtaining all approvals and meeting conditions, Enlitic anticipates a pro forma cash balance near A$18 million post-completion, sufficient to support operations until cashflow break-even. Investors will closely monitor the meeting outcome, as settlement and allotment of new securities depend entirely on shareholder consent.
Key Highlights
- Enlitic, Inc. (ASX:ENL) is a US-based AI medical imaging software company with CDIs traded on the ASX.
- An Extraordinary General Meeting is scheduled for Wednesday, 29 July 2026 to seek approval for a conditional A$15 million placement, a security purchase plan up to A$1 million, convertible note conversion into CDIs, and a 10-for-1 share consolidation.
- New CDIs in the placement are priced at A$0.004 each; convertible notes totaling A$10 million (A$1.25 per note) across 8,000,000 secured notes will convert; share consolidation expected in September 2026.
- Investors should watch for the EGM results on 29 July 2026, with settlement of new CDIs anticipated on 5 August 2026 and allotment on 6 August 2026, pending approval.
Enlitic’s AI Radiology Software and Its Role in the Capital Raise
Based in Loveland, Colorado, Enlitic develops AI-driven software products for managing medical imaging data across modalities such as MRI, CT, X-ray, and ultrasound. Licensed to healthcare providers, its platform aims to standardize, protect, integrate, and analyze imaging data to build a real-world evidence system that enhances clinical workflows, boosts operational efficiency, and expands radiology department capacity.
This capital raise aligns with Enlitic’s growth phase, as funds from the conditional placement will support ongoing commercialization, sales and marketing scale-up, working capital, and balance sheet strengthening. The company is progressing toward cashflow break-even, indicating it remains in an investment stage rather than generating positive cash flow. This context is critical for investors evaluating the proposed transactions at the 29 July 2026 EGM.
Details of the A$15 Million Conditional Placement at A$0.004 Per CDI
On 3 July 2026, Enlitic announced binding commitments to raise approximately A$15 million before costs through a placement of new fully paid CHESS Depositary Interests (New CDIs) priced at A$0.004 each. The placement is conditional on shareholder approval under ASX Listing Rules 7.1 and 10.11 (the latter relating to director participation) and on the conversion of all convertible notes into CDIs.
Because of these conditions, no New CDIs will be issued nor funds received until shareholders approve the resolutions at the 29 July 2026 EGM. The Notice of Extraordinary General Meeting sent to securityholders on 16 July 2026 outlines the required resolutions. Settlement of New CDIs is expected on 5 August 2026, with allotment and convertible note conversion on 6 August 2026, subject to approvals.
Conversion of 8 Million Secured Convertible Notes Into CDIs on Revised Terms
A key restructuring component is converting Enlitic’s 8,000,000 secured convertible notes into CDIs, contingent on shareholder approval and other conditions. The conversion will be on amended terms, totaling A$10 million aggregate value at A$1.25 per note.
This conversion reduces secured debt and converts noteholders into CDI holders. It is a prerequisite for the conditional placement, linking the two transactions. Shareholders must approve the conversion at the 29 July 2026 EGM for the package to proceed.
Security Purchase Plan Offering Up to A$1 Million for Eligible CDI Holders
In addition to the placement and note conversion, Enlitic has introduced a security purchase plan (SPP) targeting approximately A$1 million before costs. The SPP requires any necessary ASX waivers and shareholder approval, making it contingent on the EGM outcomes.
The SPP booklet and offer are expected to be released on 7 August 2026, with the offer closing on 28 August 2026. The record date for eligibility was 7:00pm AEST on 2 July 2026. Further SPP details will be provided later. The SPP proceeds are not included in the company’s pro forma cash balance of about A$18 million.
Proposed 10-for-1 Share Consolidation Scheduled for September 2026
A significant structural change is the proposed 10-for-1 share consolidation (reverse share split), which would reduce the number of CDIs outstanding by a factor of ten, consolidating every ten CDIs into one. This measure aims to increase the per-security price from a fraction of a cent to a more marketable level.
Given the A$0.004 placement price, the post-consolidation price would be approximately A$0.04 per CDI. The consolidation is expected to take effect in September 2026, after placement settlement, allotment, and SPP closure, pending shareholder approval at the EGM.
Pro Forma Cash Position of Around A$18 Million and Path to Cashflow Break-Even
Enlitic expects the conditional placement proceeds will fund operations through to cashflow break-even, with a pro forma cash balance near A$18 million post-completion, excluding potential SPP proceeds. This figure was disclosed with the 3 July 2026 announcement, with further details available in the prior investor presentation.
The milestone of cashflow break-even indicates management’s confidence that the capital raised combined with existing cash will sustain the business until it generates sufficient revenue to operate without additional external funding. However, no specific timeline or financial forecasts were provided in this update.
EGM and Transaction Timetable: From 29 July 2026 to September Consolidation
The indicative timetable shows the Extraordinary General Meeting on 29 July 2026. If approved, settlement of New CDIs is expected on 5 August 2026, with allotment and convertible note conversion on 6 August 2026. The SPP booklet is due 7 August 2026, with the offer closing 28 August 2026.
The 10-for-1 share consolidation is anticipated in September 2026 after placement and SPP completion. The timetable is indicative and may be adjusted by Enlitic. All dates are in Australian Eastern Standard Time and depend on shareholder approvals and conditions being met.
Director Participation and ASX Listing Rule 10.11 Approval
Shareholder approval is required under ASX Listing Rules 7.1 and 10.11, the latter due to proposed director participation in the placement. Separate resolutions will address director involvement, which is standard governance practice. Details are provided in the Explanatory Memorandum sent on 16 July 2026, which shareholders should review before voting.
Risks: Shareholder Approval, Dilution, and Conditional Transactions
The primary risk is that failure to pass any key resolutions at the 29 July 2026 EGM could prevent some or all transactions from proceeding. The conditional placement depends on convertible note conversion and shareholder approval, so failure of one element could derail the entire package.
Shareholders should also consider dilution risks, as the placement and note conversion will significantly increase CDIs on issue. Although the 10-for-1 consolidation reduces the number of securities, non-participating shareholders will see their ownership diluted. Enlitic operates in the healthcare AI sector, which involves regulatory, competitive, and technological risks relevant to investors.
Distribution of EGM Documents and Shareholder Access to Meeting Materials
The Notice of Extraordinary General Meeting and Explanatory Memorandum were attached to the 16 July 2026 company update and dispatched to securityholders the same day. Additional materials include a Proxy Form, CDI Voting Instruction Form, question submission form, online meeting guide, and a letter explaining participation procedures.
CDI holders should carefully review the CDI Voting Instruction Form as voting procedures differ from direct shareholding. The meeting is on 29 July 2026, and the resolution outcomes will determine whether the placement, note conversion, SPP, and share consolidation proceed as scheduled. Investors with questions can contact Enlitic Investor Relations in Australia at [email protected] or Six Degrees Investor Relations representative Henry Jordan at [email protected] or +61 431 271 538.
